PREVENTION OF WORSENING RENAL FUNCTION OF INTRAVENUS ALBUMIN IN HEART FAILURE PATIENTS

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 250 participants.

Also called NCT06630923

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 250 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06630923
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Greece (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06630923. Randomized; no masking; primary purpose prevention. Start 2023-01-14 (actual); primary completion 2025-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PREVENTION OF WORSENING RENAL FUNCTION OF INTRAVENUS ALBUMIN IN HEART FAILURE PATIENTS
Condition
Diuretics Drug Reactions
Condition
Heart Failure; With Decompensation
Condition
Albumin; Double
Intervention (Drug)
Human albumin
Lead sponsor
Democritus University of Thrace (class: other)

Record details

Record id
cardio:ct-nct06630923
Content hash
6126e4e6bcec67112859b3a212dc323acd01335f5807a74d5e1848985c836825